Balancing the Burden of Treatment for nAMD and DME

555 Canal Street,New Orleans LA 70130

13 November, 2021

Description

This program is intended for AAO attendees only. Hybrid CME Dinner SymposiumActivity ChairArshad M. Khanani, MD, MA Managing Partner Director of Clinical Research Director of Fellowship Sierra Eye Associates Clinical Associate Professor University of Nevada Reno, NV FacultyCaroline Baumal, MD Professor of Ophthalmology New England Eye Center Tufts University School of Medicine Boston, MA Carl D. Regillo, MD, FACS Director, Wills Eye Retina Service Professor of Ophthalmology Thomas Jefferson University Mid Atlantic Retina Philadelphia, PA OverviewNovel delivery systems, gene therapy, as well as agents with unique mechanisms of action that extend dosing frequency, are being assessed in clinical studies for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These innovative approaches aim to address the unmet needs of treatment burden and suboptimal treatment responses often seen in patients with retinal diseases. Unlike intravitreal injections, several of these new therapeutic modalities require specific surgical approaches that must be utilized to provide optimal outcomes and safety. In this CME activity, experts in the field will evaluate the latest efficacy and safety data for novel delivery systems and therapies with unique mechanisms of action that have the potential to lengthen the interval between treatments for nAMD and DME, as well as discuss best practices and procedures that can reduce complications with new therapeutic modalities that require unique surgical approaches. Agenda5:30 PM Registration and Dinner 6:00 PM Introduction and Pretest Arshad M. Khanani, MD, MA 6:05 PM Innovative MOAs on the Horizon That Promise to Reduce the Burden of nAMD and DME Treatment Caroline Baumal, MD 6:30 PM Panel Discussion: Innovative MOAs Moderated by Arshad M. Khanani, MD, MA 6:35 PM Differentiating Advances in Delivery for the Treatment of nAMD and DME Carl D. Regillo, MD, FACS 7:00 PM Panel Discussion: A Deeper Dive Into the PDS With Ranibizumab Moderated by Arshad M. Khanani, MD, MA 7:15 PM Posttest and Question & Answer 7:30 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Recognize the current need for treatments that reduce the burden of frequent anti-VEGF injections for the management of nAMD or DME.Summarize new evidence about novel delivery systems that may reduce the need for frequent anti-VEGF injections in patients with nAMD or DME.Outline emerging therapeutics with unique mechanisms of action that can lengthen the time between treatments for patients with nAMD or DME.Describe surgical techniques and best practices that can reduce the potential for complications when implanting and refilling the port delivery system with ranibizumab.Target AudienceThe intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with nAMD or DME. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group. This activity is not affiliated with the official program of AAO 2021. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of accredited content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be mitigated and disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance. Privacy Policy Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086